Cosmetics and Personal Care IP Toolkit: Names, Claims, Packaging, and Ingredients

By Casey Scott McKay · 2025-08-18

Cosmetics is a category where the brand carries almost all the value, the formulation is rarely patentable, and the words on the pack are regulated by several regimes at once. This toolkit collects what a practitioner needs. It works through name clearance in a crowded class, the trade dress and design filings that protect a package, and the formulation choice between patent and secrecy in a field where ingredient listing publishes the composition anyway. It then addresses the claims layer, which is where the exposure sits: the line between a cosmetic claim and a drug claim, the substantiation required for clean, natural, dermatologist tested, hypoallergenic, and cruelty free, and the influencer disclosure rules that reach every launch. It closes on the ingredient and safety documentation now required, and on the enforcement routes both ways.

IP and Technology > Trademarks | Toolkit | Published 18 August 2025 - Updated 18 March 2026 | Casey Scott McKay - marksy.us

Summary. Cosmetics is a category where the brand carries almost all the value, the formulation is rarely patentable, and the words on the pack are regulated by several regimes at once. This toolkit works through name clearance in a crowded class, the trade dress and design filings that protect a package, and the formulation choice between patent and secrecy in a field where ingredient listing publishes the composition anyway. It then addresses the claims layer, where the exposure sits: the line between a cosmetic claim and a drug claim, the substantiation required for the category's characteristic words, and the influencer disclosure rules that reach every launch.

Keywords: cosmetics IP toolkit · personal care branding · clean beauty claims · dermatologist tested · drug claims versus cosmetic claims · ingredient listing · MoCRA · substantiation · trade dress in packaging · formulation trade secrets · influencer disclosure · cruelty free claims · natural and organic claims · product name clearance · fragrance disclosure

Start Here

Almost everything valuable about a cosmetic product is on the outside of the bottle.

The formulation is rarely the differentiator. Contract manufacturers produce comparable products for many brands, ingredients are commodity, and the technical barriers to entry are low. What separates a product that sells at a premium from one that does not is the name, the package, the claims, and the story.

Which inverts the usual intellectual property priorities. Patents matter occasionally; trademarks and trade dress matter enormously; and the claims — which are advertising law rather than intellectual property — carry the largest single exposure in the category.

Three regimes govern the pack simultaneously. Trademark law governs the name and the trade dress; food, drug, and cosmetic regulation governs the ingredient listing, the safety substantiation, and — critically — whether the product has become a drug by virtue of what the label claims; and advertising law governs whether the claims are substantiated and whether the endorsements are disclosed.

The line between a cosmetic and a drug is drawn by the claim, not by the formula. A moisturiser that says it hydrates is a cosmetic; the identical product saying it repairs the skin barrier and reduces inflammation is making a structure-function claim that can convert it into an unapproved new drug.

And the category is being re-regulated. Modernised cosmetics legislation has introduced facility registration, product listing, safety substantiation records, adverse event reporting, and fragrance allergen disclosure — obligations that did not previously exist and that interact directly with the formulation secrecy strategy.

This toolkit works through brand, package, formulation, claims, and ingredients, in that order.

Naming and Clearance

The class is crowded and the naming conventions are conventional, which makes clearance harder here than in almost any consumer category.

Search widely. Federal and state registers, common law use, domain and handle availability, marketplace listings, and — because the category is global from day one — the principal foreign registers.

Assess under 15 U.S.C. § 1052(d), and expect a crowded field to cut both ways: many similar marks coexist, which weakens everyone's scope, and a citation is still a citation.

Descriptiveness is the recurring refusal. Ingredient names, benefit words, and skin-type descriptors face refusal under 15 U.S.C. § 1052(e), and a mark that is merely descriptive requires acquired distinctiveness under 15 U.S.C. § 1052(f) — which for a new brand means it is unregistrable on the principal register at launch.

Deceptive misdescriptiveness is a live risk where the name implies a characteristic the product lacks — an ingredient it does not contain, an origin it does not have, or a benefit it does not deliver.

File in the right classes. Class 3 for cosmetics and non-medicated preparations; Class 5 where the product is medicated; Class 21 for applicators and containers; Class 44 for services if the brand extends to treatment.

Watch the Class 3 to Class 5 boundary, because the same product can require different classes depending on its claims — and the classification decision is a signal about the regulatory position.

Clear the sub-brands and the product names too, because cosmetics brands generate dozens of product names annually and most are never searched.

And clear internationally before the launch, because a first-to-file jurisdiction will have the name registered by a distributor or a broker within months of a successful launch.

Packaging, Trade Dress, and Design

The package is the product in this category, and it is protected on three layers that should be sequenced deliberately.

Design patents on the container, closure, applicator, and compact under 35 U.S.C. § 171. They issue quickly, cost little, and are the only right that reaches a competitor's identical-looking bottle without proof of secondary meaning. File before any public disclosure, because 35 U.S.C. § 102 gives a one-year domestic grace period and none abroad, and a trade show reveal starts the clock.

Trade dress in the overall appearance of the packaging, protectable under 15 U.S.C. § 1125(a) and registrable where distinctive. Packaging trade dress can be inherently distinctive under Two Pesos, Inc. v. Taco Cabana, Inc., 505 U.S. 763 (1992), while product design trade dress always requires secondary meaning after Wal-Mart Stores, Inc. v. Samara Brothers, Inc., 529 U.S. 205 (2000) — and the bottle shape is frequently product design rather than packaging.

Functionality is the wall. TrafFix Devices, Inc. v. Marketing Displays, Inc., 532 U.S. 23 (2001), excludes features essential to use or affecting cost or quality, and a pump mechanism, a dispensing aperture, or a stackable shape may be functional.

Colour can be a mark after Qualitex Co. v. Jacobson Products Co., 514 U.S. 159 (1995), but only with secondary meaning and only where non-functional — and in a category where colour signals shade, that is a real constraint.

Copyright covers the graphics: illustrations, patterns, and original textual content on the pack, registrable and worth registering because 17 U.S.C. § 412 conditions statutory damages and fees on timely registration.

Sequence the filings. Design patents first, before disclosure; copyright registration at launch; trade dress registration once the evidence of distinctiveness has accumulated.

And document the secondary meaning evidence from day one — advertising spend, unsolicited media, sales volume, and any survey — because it will be needed in three years and cannot be reconstructed.

Formulation: Patent, Secret, or Neither

Ask the detectability question first, as in any chemistry.

Analytical chemistry can identify ingredients, and ingredient listing requirements publish them anyway. So the identity of what is in the product is not a secret in this category, and pretending otherwise wastes effort.

Ratios, order of addition, and processing conditions are frequently undetectable, and those are the genuine secrets — protectable under 18 U.S.C. § 1839 provided reasonable measures are taken, which means contract manufacturer obligations, access segregation, and controls on the individuals who hold the master formula.

Patents are available for genuinely novel compositions and delivery systems, and face the ordinary obviousness problem over overlapping prior art ranges plus a very large body of cosmetic prior art. Unexpected results supported by comparative data is the rebuttal, and it has to compare against the closest prior art rather than against a commercial benchmark.

Method of manufacture claims are underused and reach the contract manufacturer's process directly.

Method of use and treatment claims brush against the drug boundary and should be drafted with the regulatory position in view.

And the contract manufacturer relationship is where the formulation actually lives. Most brands do not make their own product. The master formula, the process parameters, and the improvements developed during scale-up sit with the manufacturer unless the agreement says otherwise, and a brand that changes manufacturers discovers what it does and does not own at the worst moment.

Address six things in that agreement: ownership of the formula, ownership of improvements, confidentiality reaching individuals and subcontractors, exclusivity of the formula, transfer obligations surviving termination, and minimum order and overrun controls.

The Claims Layer

This is where the exposure is, and the analysis has two independent axes.

Axis one: is it a drug claim? A cosmetic is intended to cleanse, beautify, promote attractiveness, or alter appearance. A product intended to affect the structure or function of the body, or to treat or prevent disease, is a drug. The intended use is established by labelling, marketing, website copy, social posts, and influencer statements — which means a marketing team can convert a cosmetic into an unapproved new drug without changing the formula at all.

Words that cross the line include repair, heal, restore, regenerate, stimulate, reduce inflammation, treat, prevent, and anti-bacterial, along with references to specific conditions.

Words that stay inside it describe appearance: the appearance of fine lines, the look of firmness, the feel of hydration.

Some products are both, and over-the-counter monograph products — sunscreens, antiperspirants, anti-dandruff, acne treatments — are drugs with cosmetic characteristics and carry their own labelling regime.

Axis two: is the claim substantiated? Under 15 U.S.C. § 45, every express and implied claim requires a reasonable basis at the time it is made, and for a claim implying scientific proof that means competent and reliable scientific evidence.

The category's characteristic claims each have a specific answer.

Clean. Undefined by regulation, meaning whatever the brand says it means, which is why it must be defined on the pack — typically as free of a listed set of ingredients — and the definition must be accurate.

Natural and organic. Natural is undefined; organic is defined for products meeting agricultural certification standards and is regulated where that certification is claimed.

Dermatologist tested. Means a dermatologist conducted or supervised a test. It does not mean the dermatologist approved the product or that the test showed anything, and the substantiation is the protocol and the results.

Hypoallergenic. Undefined by regulation, requiring substantiation that the product is less likely to cause an allergic reaction, which most brands using the word do not have.

Non-comedogenic. Requires testing, and the protocol matters.

Cruelty free and not tested on animals. Requires that neither the finished product nor its ingredients were tested on animals by or for the company, including by suppliers and including where required for a foreign market — the last of which catches brands entering markets with mandatory testing.

Clinically proven. The highest bar, requiring a study of appropriate design, size, and controls, and the most frequently made without it.

Influencers, Reviews, and Social

Cosmetics is the category where influencer marketing was invented, and it carries the corresponding compliance load.

The Endorsement Guides at 16 C.F.R. Part 255 require disclosure of material connections, require endorsements to reflect honest opinions and actual experience, and hold the advertiser responsible for what endorsers say.

Gifted product is a material connection, and so are affiliate commissions, discount codes, and any ongoing relationship.

Disclosure must be clear and conspicuous in the medium used — visible in video, spoken where the format is audio, and not buried in a caption or behind a "more" link.

The advertiser is responsible for the endorser's claims, including drug claims, which means an influencer saying a serum cured their acne has made a drug claim on the brand's behalf.

So brief them. A one-page brief listing permitted claims, prohibited words, and required disclosure format is the single most effective control in this area, and it is cheap.

Monitor and correct. A programme without monitoring is a programme without evidence of reasonable efforts, and the Guides look at what the advertiser did as well as what the endorser said.

Reviews and ratings raise their own issues: incentivised reviews require disclosure, review gating and suppression of negative reviews are deceptive, and fabricated reviews carry direct enforcement exposure.

And employee and founder content is endorsement too, with the material connection being the employment itself.

Ingredients, Safety, and Disclosure

The modernised cosmetics regime changed the compliance baseline, and it interacts with the intellectual property strategy directly.

Facility registration and product listing bring the manufacturer and the products into a register, with ingredient information supplied.

Safety substantiation must be documented and maintained — adequate evidence that the product is safe under labelled or customary conditions of use — which is a records obligation rather than a pre-market approval.

Adverse event reporting creates an obligation to record and, for serious events, to report, with retention periods.

Fragrance allergen disclosure requires identification of specified allergens on the label, narrowing the traditional protection of fragrance composition as a trade secret.

Ingredient labelling follows an established nomenclature with descending order by concentration and specific rules for colour additives and for incidental ingredients.

Professional and salon products have their own labelling treatment, and drop-shipping consumer-sized units of professional products creates compliance gaps.

Colour additives require pre-approval for specific uses, which is a hard constraint on formulation rather than a labelling question.

And the practical intellectual property consequence is the one this toolkit keeps returning to: the composition is disclosed, so the protectable asset is the brand, the package, the process, and the accumulated claim substantiation — not the recipe.

Enforcement, In Both Directions

Against copyists. Cosmetics attracts dupes, and the response depends on what was copied. A copied bottle shape reaches a design patent claim; a copied graphic reaches copyright with statutory damages if registered under 17 U.S.C. § 412; a copied name reaches trademark; and a copied overall look reaches trade dress if distinctiveness and non-functionality can be shown.

Counterfeits are a separate problem with better tools: customs recordation under 19 U.S.C. § 1526, ex parte seizure under 15 U.S.C. § 1116(d), statutory damages under 15 U.S.C. § 1117, and marketplace brand registry programmes that act faster than any court.

Counterfeit cosmetics carry a safety dimension that changes the calculus: contaminated product bearing the brand's name is a consumer safety issue and a public relations event, and it justifies enforcement spending that ordinary infringement would not.

Gray goods are genuine units sold outside authorised channels, and the claim requires a material difference — different formulation for a foreign market, different labelling, absent batch traceability, or expired product — under the reasoning of Lever Bros. Co. v. United States, 981 F.2d 1330 (D.C. Cir. 1993).

Against your claims. Competitors challenge under 15 U.S.C. § 1125(a) with standing determined by Lexmark International, Inc. v. Static Control Components, Inc., 572 U.S. 118 (2014); consumer class actions follow packaging claims; and the self-regulatory advertising process is fast and frequently the best first venue.

And note POM Wonderful LLC v. Coca-Cola Co., 573 U.S. 102 (2014) — compliance with a labelling regime does not necessarily preclude a false advertising claim, so "the label complies" is not a complete defence.

Building the Programme

Clear the house mark properly and the product names systematically, with a standing process rather than a launch scramble.

File design patents on every distinctive container, closure, and applicator before disclosure.

Register the copyright in pack graphics at launch, inside the window that preserves statutory damages.

Build the secondary meaning file from the first campaign.

Run one artwork review covering trademark, regulatory, and advertising in a single pass, at concept rather than at proof.

Maintain a claims register — every claim, its substantiation, its methodology, its date, and its owner — across pack, website, retailer listings, and social.

Screen every claim against the drug boundary, and treat the marketing copy as a regulatory document.

Brief the influencers, monitor the output, and keep the records.

Contract the manufacturer for formula ownership, improvements, confidentiality reaching individuals, exclusivity, transfer on termination, and overrun control.

Maintain the safety substantiation and adverse event records as required, and align the fragrance disclosure with whatever secrecy position remains.

And re-substantiate on every change — reformulation, supplier change, new market, or new claim.

A Worked Example

A brand launches a serum described as "clean, dermatologist tested, clinically proven to repair the skin barrier," in a distinctive frosted bottle, promoted by influencers who received free product.

"Repair the skin barrier" is a structure-function claim and may convert the product into an unapproved new drug. The fix is appearance language — the look of a smoother, more resilient complexion — and it costs nothing.

"Clinically proven" requires a study, and the brand has a consumer perception panel of thirty people, which is not one. Either the claim goes or the study is commissioned.

"Dermatologist tested" requires a test, and the brand has a dermatologist on its advisory board, which is not the same thing — and is itself a material connection requiring disclosure when that dermatologist posts.

"Clean" must be defined, and the definition must be accurate against the actual formulation including incidental ingredients.

The bottle is protectable — a design patent if filed before the trade show, and trade dress later once distinctiveness accumulates — and the brand disclosed it at a trade show eleven months ago, which means the domestic clock has three weeks left and the foreign rights are gone.

The influencers disclosed in the caption below the fold, which is not clear and conspicuous, and one of them said the serum cleared her eczema — a drug claim made on the brand's behalf.

Six findings, one launch, and the remediation is a fortnight of copy changes, one urgent design filing, an influencer brief, and a claims register. None of it is litigation, and all of it would have been free two months earlier.

Retail, Distribution, and Channel Control

Where the product is sold shapes the intellectual property strategy more than most brands expect.

Prestige and selective distribution depends on controlling who sells and how, and the instrument is contract rather than trademark: authorised retailer agreements with presentation standards, minimum advertised pricing where lawful, and termination rights for diversion.

Exhaustion limits what trademark can do. Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360 (2017), confirms that an authorised sale exhausts patent rights, and the trademark analogue means genuine goods resold outside the authorised channel are generally lawful — unless a material difference exists.

So build the material difference deliberately. Batch coding, freshness dating, market-specific formulation, authorised-retailer-only sizes, warranty and authenticity programmes, and consumer-facing verification each create a genuine difference between an authorised unit and a diverted one.

Marketplace enforcement runs on brand registry programmes, test buys, and takedown, and it works far better with a registered mark, a design patent, and a registered pack graphic than with a general assertion of unfair competition.

Diversion originates in the supply chain, and the contractual controls are order-linked component supply, serialisation, and audit — the same architecture as any overrun problem.

Salon and professional channels create their own exposure, because professional-sized units diverted into consumer channels are frequently mislabelled for that use.

And international distribution requires registration ahead of entry, because a distributor in a first-to-file market who registers the mark controls the brand's access to that market entirely.

Sustainability and Refill Claims

The category has moved into environmental claiming, which brings the Green Guides at 16 C.F.R. Part 260 alongside everything else.

Recyclable claims for a pump bottle require that recycling be available to a substantial majority of consumers where sold, and pumps and mixed-material closures frequently are not accepted.

Recycled content requires a stated percentage, a pre- versus post-consumer distinction, and traceable supply chain evidence.

Refillable systems raise a trademark question as well as an environmental one: a refill sold by a third party for the brand's container is a compatible product, and the nominative use rules of Prestonettes, Inc. v. Coty, 264 U.S. 359 (1924), and Champion Spark Plug Co. v. Sanders, 331 U.S. 125 (1947), govern how it may be described.

Carbon claims are the highest-exposure statements available, requiring boundary definition, reduction before offsetting, and retired credits of established quality.

Waterless, biodegradable, and plastic-free claims each have specific requirements, and biodegradable is the most constrained of all.

And the claims register should cover these alongside the efficacy claims, because they are made by the same team, on the same pack, under the same substantiation standard.

Collaborations, Licensing, and Celebrity Brands

The category runs on collaboration, and each structure has a different ownership answer.

Celebrity and creator brands are personality licences, and the terms that matter are what happens to the mark on termination, whether the name reverts, the scope of the personality rights granted, approval rights over product and creative, and post-term restrictions on competing ventures. A brand built on a person's name whose licence terminates has lost the asset, and the negotiation should assume that outcome rather than hope against it.

Right of publicity grants should be specific about media, territory, term, and — increasingly — synthetic and generated likeness, because a general grant of name and likeness executed years ago did not contemplate it.

Retailer collaborations raise ownership of jointly developed packaging and formulations, and exclusivity terms that constrain the brand's other channels.

Designer and artist collaborations produce artwork that the artist owns absent an assignment, and a limited edition pack whose illustration was never assigned cannot be reissued.

Ingredient brand licensing — a trademarked active licensed into a formulation — carries usage guidelines, minimum inclusion levels, claim restrictions, and audit rights, and misuse is a licence breach as well as a claim problem.

Influencer equity arrangements blend endorsement and ownership, and the material connection disclosure obligations under 16 C.F.R. Part 255 are heavier, not lighter, where the endorser has a stake.

And white label and private label arrangements invert the analysis: the retailer owns the brand and the manufacturer owns the formula, with the contract deciding everything else.

Scale and Cadence

An indie launch needs the house mark cleared and filed, design patents on any distinctive container before disclosure, artwork copyright registered, a claims register, and an influencer brief. That is a few thousand dollars and it covers most of the exposure.

A growth brand adds systematic product name clearance, the secondary meaning file, international filings ahead of distribution, manufacturer contract terms, and a standing artwork review at concept stage.

An established portfolio adds channel control and material difference architecture, marketplace enforcement, counterfeit programmes with customs recordation, and a claims register maintained across every retailer listing — which is where unreviewed copy proliferates.

A licensor or collaborator adds the personality and reversion terms, approval rights, and post-term restrictions.

Review the claims register quarterly and on every reformulation, supplier change, new market, and new campaign.

Review the rights register annually, with renewal dates, use evidence, and any gap between the products sold and the classes registered.

And review the artwork at concept, always, because every downstream problem in this category is cheaper to fix before the plates are cut.

A Ninety-Day Programme

Days one to ten. Build the rights register: marks by class and territory, design patents by product, copyright registrations by artwork, and the gaps against what is actually sold.

Days ten to twenty. Build the claims register across pack, website, retailer listings, sales collateral, and social. It is always longer than expected, and retailer listings are where the unreviewed copy lives.

Days twenty to thirty-five. Screen every claim against the drug boundary and against the substantiation standard, and mark each as supported, unsupported, or requiring work.

Days thirty-five to forty-five. Delete or rewrite the unsupported claims, starting with the structure-function language, which is the highest-exposure category and the cheapest to fix.

Days forty-five to sixty. Audit the design disclosure position: what has been shown publicly, when, and whether any 35 U.S.C. § 102 grace period is still running on a container worth protecting.

Days sixty to seventy-five. Read the contract manufacturer agreement against the six terms, and the influencer arrangements against the disclosure requirements.

Days seventy-five to ninety. Establish the artwork review at concept stage, the influencer brief and monitoring log, and the quarterly claims review with its change triggers.

The output is two registers, one review gate, and a short filing list, and it is achievable inside a launch calendar rather than alongside it.

A Closing Note

Cosmetics is the clearest case in this library of a category where the intellectual property function is asked the wrong question.

Founders arrive asking whether the formula can be patented. Usually it cannot, usefully; the ingredients will be disclosed on the label regardless; and the money spent on a weak composition filing would have been better spent on a design patent for the bottle and a claims review before the copy was locked.

Meanwhile the actual assets accumulate unprotected. A distinctive container disclosed at a trade show eleven months ago. Pack artwork commissioned without an assignment. A house mark unregistered in the market the brand is about to enter. A claims set that converts a cosmetic into a drug in three words.

And the actual exposure accumulates too. Influencer copy nobody briefed, retailer listings nobody reviewed, and a "clinically proven" claim resting on a thirty-person perception panel.

None of that requires sophisticated advice. It requires two registers, one review gate, and someone willing to say that the formula is not the asset.

Say it early. In this category the difference between a brand that has something to sell in five years and one that does not is decided in the first six months, by decisions that cost almost nothing and are almost never taken.

What Clients Actually Ask

"Can we patent our formula?" Occasionally, and it usually is not worth it. The ingredients will appear on the label, the prior art is enormous, and the process conditions — which are the real know-how — are better kept as a secret under 18 U.S.C. § 1839.

"Can we say it repairs skin?" Not as a cosmetic. Repair, heal, restore, and regenerate are structure-function language, and the fix is appearance language that costs nothing and sells equally well.

"Everyone says clinically proven." Everyone who says it without a study is exposed, and the first competitor to build a substantiation file has an easy challenge to bring.

"Our bottle is unique — is it protected?" If you filed a design patent before showing it, yes. If you showed it first, you may have weeks left domestically and nothing abroad. Ask this question before the trade show, not after.

"Do we need to register the mark abroad before we sell there?" Yes, and before you announce there. A distributor or broker in a first-to-file market will otherwise own your name in that market.

"Who owns the illustration on the limited edition?" The illustrator, unless you took an assignment. This is discovered when the edition is reissued.

"What is our biggest exposure?" The retailer product description page, written by someone at the retailer from your press release, containing a claim you never approved and cannot substantiate.

Adjacent Categories

Supplements and ingestibles are regulated differently again, with structure-function claims permitted subject to a disclaimer and notification, and with an entirely separate labelling regime. A brand extending from topical into ingestible has changed regulatory categories, not just product formats.

Devices — cleansing tools, light therapy, microcurrent — are devices, with intended use again determined by the marketing copy, and with a clearance pathway that a cosmetics team will not have encountered.

Over-the-counter monograph products — sunscreen, acne, anti-dandruff, antiperspirant — are drugs with a defined labelling format, active ingredient statement, and permitted claim set, and they cannot carry the free-form claims a cosmetic can.

Professional and clinical channels carry their own labelling and, where a licensed practitioner administers the product, an entirely different set of constraints.

Fragrance sits partly outside the general disclosure regime and increasingly inside it, and the traditional secrecy of a fragrance composition is narrowing.

Pet care and household are adjacent categories with their own regimes and are frequently added to a personal care portfolio without a regulatory review.

And in each case the same discipline applies: establish the regulatory category before the copy is written, because the category is determined by the copy.

Working With the Brand Team

The people who create the exposure in this category are creative, fast, and not adversarial, and the way to get compliance is to make it usable rather than to make it a gate they route around.

Give them a word list. Permitted claims, prohibited words, and the appearance-language alternatives to the structure-function phrases they instinctively reach for. One page, laminated, on the wall of the copy team.

Give them the substantiation early. A team that knows which claims are supported will use them, and a team that does not will invent claims that sound similar and are not.

Come in at concept. Reviewing artwork at proof stage means saying no when the cost of yes has already been incurred, which is how legal acquires a reputation for obstruction.

Explain the design patent deadline in their language: show it publicly and you lose the ability to protect the bottle everywhere except here, and here only for a year. Creative teams protect what they made once they understand it can be taken.

And celebrate the enforcement wins internally. A brand team that has seen a dupe pulled from a marketplace because the bottle had a design patent will file the next one without being asked, which is worth more than any policy.

The same applies to claims. A team that has watched a competitor withdraw a launch after a challenge understands the claims register immediately, and a team that has only been told about it will treat it as paperwork. In a category built on speed and creativity, the compliance that survives is the compliance that has been made concrete.

One further habit is worth building. Keep a folder of the category's enforcement outcomes — the withdrawn claims, the pulled dupes, the customs seizures, the consent orders — and circulate two or three each quarter. It takes ten minutes, it costs nothing, and it does more to change behaviour than any training session, because it shows the brand team that the rules in this toolkit describe things that happen to companies like theirs rather than abstractions.

It is also the least expensive item in this toolkit and, measured by behaviour changed per hour spent, comfortably the most effective.

Start it the week you finish the two registers, and it will outlast every other control described here.

A Suggested Reading Path

Start with the doctrine in Clean, Natural, Dermatologist Tested.

Then the practice in Launching a Cosmetics or Personal Care Brand.

Then the audit in the cosmetics and personal care IP checklist.

For clearance, the Trademark Clearance and Brand Selection Toolkit and the trademark clearance search checklist.

For the package, Three Ways to Own a Shape, the Trade Dress and Product Design Toolkit, and the Layered Design Protection Toolkit.

For claims and endorsements, Endorsements, Influencers, and the Law of Paid Praise, Building an Influencer and Endorsement Compliance Program, and the Advertising and Marketing Law Toolkit.

For labelling, Made Where?, Getting a Label Right, and the Origin, Labelling, and Packaging Toolkit.

For the formulation, Claiming a Compound and the Chemicals, Materials, and Formulations IP Toolkit.

For the manufacturer relationship, Contracting With a Manufacturer and the Contract Manufacturing, OEM, and Private Label IP Toolkit.

And for counterfeits and gray goods, the Anticounterfeiting and Border Enforcement Toolkit and the gray market and exhaustion checklist.

Primary Authorities

| Authority | Proposition | |---|---| | 15 U.S.C. § 1052(d) | Likelihood of confusion in a crowded class | | 15 U.S.C. § 1052(e) | Descriptiveness; deceptive misdescriptiveness | | 15 U.S.C. § 1052(f) | Acquired distinctiveness | | 15 U.S.C. § 1125(a) | Trade dress; false advertising | | 15 U.S.C. § 1116(d) | Ex parte seizure in counterfeiting | | 15 U.S.C. § 1117 | Remedies; statutory damages | | 15 U.S.C. § 45 | Unfair or deceptive acts; substantiation | | 16 C.F.R. Part 255 | Endorsement Guides | | 16 C.F.R. Part 260 | Environmental marketing claims | | 21 U.S.C. § 321 | Cosmetic and drug definitions; intended use | | 21 U.S.C. § 331 | Prohibited acts; misbranding | | 21 C.F.R. Part 701 | Cosmetic labelling | | 21 C.F.R. Part 700 | General cosmetic requirements | | 19 U.S.C. § 1526 | Customs recordation | | 35 U.S.C. § 171 | Design patents on containers and applicators | | 35 U.S.C. § 102 | Novelty; disclosure at trade shows | | 17 U.S.C. § 412 | Statutory damages and fees for pack graphics | | 18 U.S.C. § 1839 | Trade secret; formulation and process | | Wal-Mart Stores v. Samara Brothers | Product design requires secondary meaning | | Two Pesos v. Taco Cabana | Packaging may be inherently distinctive | | TrafFix Devices v. Marketing Displays | Functionality bar | | Qualitex v. Jacobson Products | Colour as a mark | | Lexmark International v. Static Control Components | Standing for false advertising | | POM Wonderful v. Coca-Cola | Regulatory compliance is not a complete defence | | Lever Bros. v. United States | Material differences in gray goods | | Modernised cosmetics regulation obligations | Registration, listing, safety records | | Fragrance allergen disclosure | Narrowing fragrance secrecy |

Forms and Templates

The License Agreement Template supplies the structure for a contract manufacturing or private label agreement, and the terms that decide the outcome are formula ownership, improvements, confidentiality reaching individual operators and subcontractors, exclusivity of the formula, transfer obligations surviving termination, and overrun and metering controls. The Assignment Agreement Template covers designers, photographers, copywriters, and packaging agencies, all of whom own what they create absent an assignment. The Portfolio Inventory Template adapts into the two registers this category needs: a rights register covering marks by class and territory, design patents by product, and copyright registrations by artwork; and a claims register covering every claim, its substantiation, its methodology, and its owner. Beyond those, keep three records: a secondary meaning file built from launch; an influencer brief with monitoring logs; and the safety substantiation and adverse event records the current regime requires.

Related Toolkits and Checklists

The Trademark Clearance and Brand Selection Toolkit covers naming in a crowded class. The Trade Dress and Product Design Toolkit covers the package. The Advertising and Marketing Law Toolkit covers substantiation and competitor challenge. The Origin, Labelling, and Packaging Toolkit covers the artwork review that catches most problems, and the Anticounterfeiting and Border Enforcement Toolkit covers the counterfeit exposure that is unusually acute in this category.